XNASATNF
Market cap5mUSD
Dec 26, Last price
2.83USD
1D
-2.41%
1Q
68.45%
IPO
-99.92%
Name
180 Life Sciences Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
106.89%
Rev. gr., 5y
%
Revenues
0k
Net income
-20m
L-48.52%
CFO
-11m
L-9.94%
Earnings
Mar 20, 2025
Profile
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | 13,583 | 18,007 | 15,757 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (13,583) | (18,007) | (15,757) | ||||
NOPBT Margin | |||||||
Operating Taxes | (2,349) | 943 | 23 | ||||
Tax Rate | |||||||
NOPAT | (11,234) | (18,950) | (15,781) | ||||
Net income | (19,935) -48.52% | (38,726) 90.54% | (20,325) 69.28% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 5,999 | 11,485 | 26,666 | ||||
BB yield | -390.14% | -178.27% | -21.81% | ||||
| Debt | |||||||
Debt current | 1,034 | 1,309 | 1,909 | ||||
Long-term debt | 20 | 31 | 48 | ||||
Deferred revenue | (31,189,000) | (48,165,000) | |||||
Other long-term liabilities | 31,189,000 | 48,165,000 | |||||
Net debt | (922) | (5,630) | (6,267) | ||||
| Cash flow | |||||||
Cash from operating activities | (10,922) | (12,128) | (19,371) | ||||
CAPEX | 3 | ||||||
Cash from investing activities | |||||||
Cash from financing activities | 5,908 | 10,874 | 25,412 | ||||
FCF | (10,845) | (25,539) | (22,930) | ||||
| Balance | |||||||
Cash | 1,976 | 6,970 | 8,225 | ||||
Long term investments | |||||||
Excess cash | 1,976 | 6,970 | 8,225 | ||||
Stockholders' equity | (130,245) | (110,294) | (67,861) | ||||
Invested Capital | 131,171 | 122,977 | 109,142 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 379 | 100 | 83 | ||||
Price | 4.06 -93.70% | 64.41 -95.65% | 1,482.00 42.86% | ||||
Market cap | 1,538 -76.13% | 6,442 -94.73% | 122,286 146.74% | ||||
EV | 616 | 812 | 116,019 | ||||
EBITDA | (13,478) | (17,898) | (15,647) | ||||
EV/EBITDA | |||||||
Interest | 27 | 186 | |||||
Interest/NOPBT | |||||||